Marble Harbor Investment Counsel LLC Lowers Stock Position in DexCom, Inc. $DXCM

Marble Harbor Investment Counsel LLC reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.8% during the second quarter, HoldingsChannel.com reports. The fund owned 158,655 shares of the medical device company’s stock after selling 6,341 shares during the quarter. DexCom makes up approximately 1.5% of Marble Harbor Investment Counsel LLC’s investment portfolio, making the stock its 21st largest position. Marble Harbor Investment Counsel LLC’s holdings in DexCom were worth $13,849,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DXCM. Andra AP fonden purchased a new stake in DexCom in the 2nd quarter worth about $26,000. Zions Bancorporation National Association UT bought a new position in shares of DexCom in the first quarter worth $27,000. Anderson Financial Strategies LLC purchased a new position in DexCom during the first quarter worth about $37,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of DexCom during the second quarter worth about $45,000. Finally, Atlantic Union Bankshares Corp purchased a new position in DexCom in the 2nd quarter worth approximately $70,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the transaction, the executive vice president directly owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. This represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach bought 18,200 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was purchased at an average price of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the purchase, the chief operating officer directly owned 331,697 shares in the company, valued at $18,256,602.88. The trade was a 5.81% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold a total of 9,331 shares of company stock valued at $652,085 in the last 90 days. Corporate insiders own 0.32% of the company’s stock.

DexCom Trading Up 6.0%

NASDAQ:DXCM opened at $58.13 on Wednesday. The company has a market cap of $22.67 billion, a PE ratio of 40.37, a P/E/G ratio of 1.43 and a beta of 1.40. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $93.25. The business’s 50 day moving average is $68.51 and its two-hundred day moving average is $77.51. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.57 by $0.04. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same quarter in the prior year, the firm earned $0.45 earnings per share. The company’s quarterly revenue was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. On average, analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

DXCM has been the subject of a number of recent research reports. Wells Fargo & Company set a $93.00 price objective on shares of DexCom and gave the stock an “overweight” rating in a report on Friday, October 31st. Canaccord Genuity Group set a $99.00 target price on DexCom and gave the company a “buy” rating in a research note on Friday, October 31st. Weiss Ratings restated a “hold (c-)” rating on shares of DexCom in a report on Wednesday, October 8th. Argus reduced their target price on shares of DexCom from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Finally, Morgan Stanley reduced their price objective on DexCom from $89.00 to $63.00 and set an “equal weight” rating for the company in a research report on Monday. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.62.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.